These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 20224931)

  • 1. Probiotic-induced reduction of gastrointestinal oxalate absorption in healthy subjects.
    Okombo J; Liebman M
    Urol Res; 2010 Jun; 38(3):169-78. PubMed ID: 20224931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute probiotic ingestion reduces gastrointestinal oxalate absorption in healthy subjects.
    Al-Wahsh I; Wu Y; Liebman M
    Urol Res; 2012 Jun; 40(3):191-6. PubMed ID: 21874572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of gut microbiota against calcium oxalate.
    Sadaf H; Raza SI; Hassan SW
    Microb Pathog; 2017 Aug; 109():287-291. PubMed ID: 28624518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease.
    Siva S; Barrack ER; Reddy GP; Thamilselvan V; Thamilselvan S; Menon M; Bhandari M
    BJU Int; 2009 Jan; 103(1):18-21. PubMed ID: 19021605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probiotic properties of Oxalobacter formigenes: an in vitro examination.
    Ellis ML; Dowell AE; Li X; Knight J
    Arch Microbiol; 2016 Dec; 198(10):1019-1026. PubMed ID: 27449000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A human strain of Oxalobacter (HC-1) promotes enteric oxalate secretion in the small intestine of mice and reduces urinary oxalate excretion.
    Hatch M; Freel RW
    Urolithiasis; 2013 Oct; 41(5):379-84. PubMed ID: 23959075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal Oxalobacter formigenes colonization in calcium oxalate stone formers and its relation to urinary oxalate.
    Troxel SA; Sidhu H; Kaul P; Low RK
    J Endourol; 2003 Apr; 17(3):173-6. PubMed ID: 12803990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacter formigenes.
    Sidhu H; Allison MJ; Chow JM; Clark A; Peck AB
    J Urol; 2001 Oct; 166(4):1487-91. PubMed ID: 11547118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of urinary stone disease by a multi-species bacterial network ensures healthy oxalate homeostasis.
    Miller AW; Choy D; Penniston KL; Lange D
    Kidney Int; 2019 Jul; 96(1):180-188. PubMed ID: 31130222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lowering urinary oxalate excretion to decrease calcium oxalate stone disease.
    Holmes RP; Knight J; Assimos DG
    Urolithiasis; 2016 Feb; 44(1):27-32. PubMed ID: 26614109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxalobacter formigenes colonization normalizes oxalate excretion in a gastric bypass model of hyperoxaluria.
    Canales BK; Hatch M
    Surg Obes Relat Dis; 2017 Jul; 13(7):1152-1157. PubMed ID: 28552742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal transport of an obdurate anion: oxalate.
    Hatch M; Freel RW
    Urol Res; 2005 Feb; 33(1):1-16. PubMed ID: 15565438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Forty Years of Oxalobacter formigenes, a Gutsy Oxalate-Degrading Specialist.
    Daniel SL; Moradi L; Paiste H; Wood KD; Assimos DG; Holmes RP; Nazzal L; Hatch M; Knight J
    Appl Environ Microbiol; 2021 Aug; 87(18):e0054421. PubMed ID: 34190610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion.
    Hatch M; Cornelius J; Allison M; Sidhu H; Peck A; Freel RW
    Kidney Int; 2006 Feb; 69(4):691-8. PubMed ID: 16518326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a probiotic to decrease enteric hyperoxaluria.
    Lieske JC; Goldfarb DS; De Simone C; Regnier C
    Kidney Int; 2005 Sep; 68(3):1244-9. PubMed ID: 16105057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxalate-degrading bacteria of the human gut as probiotics in the management of kidney stone disease.
    Abratt VR; Reid SJ
    Adv Appl Microbiol; 2010; 72():63-87. PubMed ID: 20602988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration.
    Campieri C; Campieri M; Bertuzzi V; Swennen E; Matteuzzi D; Stefoni S; Pirovano F; Centi C; Ulisse S; Famularo G; De Simone C
    Kidney Int; 2001 Sep; 60(3):1097-105. PubMed ID: 11532105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy.
    Sidhu H; Schmidt ME; Cornelius JG; Thamilselvan S; Khan SR; Hesse A; Peck AB
    J Am Soc Nephrol; 1999 Nov; 10 Suppl 14():S334-40. PubMed ID: 10541258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis.
    Hoppe B; von Unruh GE; Blank G; Rietschel E; Sidhu H; Laube N; Hesse A
    Am J Kidney Dis; 2005 Sep; 46(3):440-5. PubMed ID: 16129205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxalobacter formigenes: Opening the door to probiotic therapy for the treatment of hyperoxaluria.
    Jairath A; Parekh N; Otano N; Mishra S; Ganpule A; Sabnis R; Desai M
    Scand J Urol; 2015; 49(4):334-7. PubMed ID: 25645091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.